Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth.

[1]  S. Horvath,et al.  Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance , 2010, Nature Medicine.

[2]  James C. Liao,et al.  Trimming of mammalian transcriptional networks using network component analysis , 2010, BMC Bioinformatics.

[3]  Jiaoti Huang,et al.  Identification of a Cell of Origin for Human Prostate Cancer , 2010, Science.

[4]  R. Taschereau,et al.  Rank–rank hypergeometric overlap: identification of statistically significant overlap between gene-expression signatures , 2010, Nucleic acids research.

[5]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[6]  Zhaohui S. Qin,et al.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. , 2010, Cancer cell.

[7]  A. Malek,et al.  ETS Transcription Factors Control Transcription of EZH2 and Epigenetic Silencing of the Tumor Suppressor Gene Nkx3.1 in Prostate Cancer , 2010, PloS one.

[8]  J. Humm,et al.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study , 2010, The Lancet.

[9]  Huiqing Yuan,et al.  Suppression of the androgen receptor function by quercetin through protein–protein interactions of Sp1, c-Jun, and the androgen receptor in human prostate cancer cells , 2010, Molecular and Cellular Biochemistry.

[10]  Su Qu,et al.  PI3K-AKT-mTOR Pathway is Dominant over Androgen Receptor Signaling in Prostate Cancer Cells , 2010, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[11]  S. Memarzadeh,et al.  Basal epithelial stem cells are efficient targets for prostate cancer initiation , 2010, Proceedings of the National Academy of Sciences.

[12]  Liewei Wang,et al.  Emerging role of FKBP51 in AKT kinase/protein kinase B signaling , 2010, Cell cycle.

[13]  C. Cooper,et al.  Steroid hormone receptors in prostate cancer: a hard habit to break? , 2009, Cancer cell.

[14]  O. Witte,et al.  Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. , 2009, Cancer research.

[15]  N. Cho,et al.  Pathological effects of prostate cancer correlate with neuroendocrine differentiation and PTEN expression after bicalutamide monotherapy. , 2009, The Journal of urology.

[16]  V. Baron,et al.  Is EGR1 a potential target for prostate cancer therapy? , 2009, Future oncology.

[17]  P. Majumder,et al.  Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. , 2009, Cancer research.

[18]  Krishna R. Kalari,et al.  FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. , 2009, Cancer cell.

[19]  G. Attard,et al.  Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. , 2009, Cancer research.

[20]  H. Scher,et al.  Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.

[21]  R. Hill,et al.  PTEN, Stem Cells, and Cancer Stem Cells* , 2009, Journal of Biological Chemistry.

[22]  David Handelsman,et al.  Androgen sensitivity of prostate epithelium is enhanced by postnatal androgen receptor inactivation. , 2009, American journal of physiology. Endocrinology and metabolism.

[23]  W. Gerald,et al.  Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. , 2008, The Journal of clinical investigation.

[24]  S. Yeh,et al.  Targeting the stromal androgen receptor in primary prostate tumors at earlier stages , 2008, Proceedings of the National Academy of Sciences.

[25]  Jorge Yao,et al.  Androgen receptor is a tumor suppressor and proliferator in prostate cancer , 2008, Proceedings of the National Academy of Sciences.

[26]  H. Scher,et al.  Targeting the androgen receptor pathway in prostate cancer. , 2008, Current opinion in pharmacology.

[27]  P. Nelson,et al.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.

[28]  S. Yeh,et al.  Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor , 2007, Proceedings of the National Academy of Sciences.

[29]  Shunyou Wang,et al.  Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. , 2007, Cancer research.

[30]  P. Nelson,et al.  Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. , 2007, Cancer research.

[31]  David Handelsman,et al.  Disruption of prostate epithelial androgen receptor impedes prostate lobe-specific growth and function. , 2007, Endocrinology.

[32]  A. Newton,et al.  PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. , 2007, Molecular cell.

[33]  Z. Modrušan,et al.  Expression profiling of the mouse prostate after castration and hormone replacement: implication of H-cadherin in prostate tumorigenesis. , 2007, Differentiation; research in biological diversity.

[34]  M. Shen,et al.  Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice. , 2006, Cancer research.

[35]  M. Gleave,et al.  NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. , 2006, Cancer cell.

[36]  S. Abdulkadir,et al.  Enhanced EGR1 activity promotes the growth of prostate cancer cells in an androgen‐depleted environment , 2006, Journal of cellular biochemistry.

[37]  A. Newton,et al.  PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. , 2005, Molecular cell.

[38]  S. Horvath,et al.  Antibody-Based Profiling of the Phosphoinositide 3-Kinase Pathway in Clinical Prostate Cancer , 2004, Clinical Cancer Research.

[39]  Chawnshang Chang,et al.  Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. , 2004, Molecular endocrinology.

[40]  Shunyou Wang,et al.  PTENless means more. , 2004, Developmental biology.

[41]  M. Griswold,et al.  Androgen-Regulated Genes in the Murine Epididymis1 , 2004, Biology of reproduction.

[42]  Daniel J. Freeman,et al.  PTEN Regulates Mdm2 Expression through the P1 Promoter* , 2004, Journal of Biological Chemistry.

[43]  T. Golub,et al.  mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways , 2004, Nature Medicine.

[44]  P. Carmeliet,et al.  A Sertoli cell-selective knockout of the androgen receptor causes spermatogenic arrest in meiosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[45]  R. Tibshirani,et al.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Chawnshang Chang,et al.  Suppression Versus Induction of Androgen Receptor Functions by the Phosphatidylinositol 3-Kinase/Akt Pathway in Prostate Cancer LNCaP Cells with Different Passage Numbers* , 2003, Journal of Biological Chemistry.

[47]  P. Nelson,et al.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. , 2003, Cancer cell.

[48]  T. Graeber,et al.  Myc-driven murine prostate cancer shares molecular features with human prostate tumors. , 2003, Cancer cell.

[49]  R. Minchin,et al.  Immunophilin chaperones in steroid receptor signalling. , 2003, Current topics in medicinal chemistry.

[50]  Hubert Vesselle,et al.  Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. , 2003, Human pathology.

[51]  S. Hayward,et al.  Role of stroma in carcinogenesis of the prostate. , 2002, Differentiation; research in biological diversity.

[52]  M. Loda,et al.  The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer? , 2002, Cancer cell.

[53]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[54]  Biaoyang Lin,et al.  The program of androgen-responsive genes in neoplastic prostate epithelium , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[55]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[56]  P. Roy-Burman,et al.  Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation , 2001, Mechanisms of Development.

[57]  P. Humphrey,et al.  Impaired prostate tumorigenesis in Egr1-deficient mice , 2001, Nature Medicine.

[58]  J. Manola,et al.  Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. , 1999, The New England journal of medicine.

[59]  M. Gleave,et al.  Androgenic Induction of Prostate-specific Antigen Gene Is Repressed by Protein-Protein Interaction between the Androgen Receptor and AP-1/c-Jun in the Human Prostate Cancer Cell Line LNCaP* , 1997, The Journal of Biological Chemistry.

[60]  M. Soloway,et al.  Small cell carcinoma of the bladder and prostate. , 1995, Urology.

[61]  R. Matusik,et al.  Prostate cancer in a transgenic mouse. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[62]  G. Cunha.  Role of mesenchymal‐epithelial interactions in normal and abnormal development of the mammary gland and prostate , 1994, Cancer.

[63]  C. Logothetis,et al.  Small cell carcinoma of the prostate part I a clinicopathologic study of 20 cases , 1987, Cancer.

[64]  L. Chung,et al.  Stromal-epithelial interactions--I. Induction of prostatic phenotype in urothelium of testicular feminized (Tfm/y) mice. , 1981, Journal of steroid biochemistry.

[65]  Miriam Scadeng,et al.  Development of a novel mouse glioma model using lentiviral vectors , 2009, Nature Medicine.

[66]  Jeffrey A. Magee,et al.  Direct, androgen receptor-mediated regulation of the FKBP5 gene via a distal enhancer element. , 2006, Endocrinology.